Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis
• Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced b...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Holtick, Udo [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: miR-214 in stroma cells and tumor progression - Dettori, D. ELSEVIER, 2016, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:94 ; year:2015 ; number:2 ; pages:179-188 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.critrevonc.2014.12.007 |
|---|
| Katalog-ID: |
ELV039853918 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV039853918 | ||
| 003 | DE-627 | ||
| 005 | 20230625230105.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2014.12.007 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015017000005.pica |
| 035 | |a (DE-627)ELV039853918 | ||
| 035 | |a (ELSEVIER)S1040-8428(14)00215-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.52 |2 bkl | ||
| 100 | 1 | |a Holtick, Udo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis |
| 264 | 1 | |c 2015transfer abstract | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. | ||
| 520 | |a • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. | ||
| 650 | 7 | |a Graft versus host disease |2 Elsevier | |
| 650 | 7 | |a Stem cell source |2 Elsevier | |
| 650 | 7 | |a Peripheral blood |2 Elsevier | |
| 650 | 7 | |a Bone marrow |2 Elsevier | |
| 650 | 7 | |a Allogeneic stem cell transplantation |2 Elsevier | |
| 700 | 1 | |a Albrecht, Melanie |4 oth | |
| 700 | 1 | |a Chemnitz, Jens M. |4 oth | |
| 700 | 1 | |a Theurich, Sebastian |4 oth | |
| 700 | 1 | |a Shimabukuro-Vornhagen, Alexander |4 oth | |
| 700 | 1 | |a Skoetz, Nicole |4 oth | |
| 700 | 1 | |a Scheid, Christof |4 oth | |
| 700 | 1 | |a von Bergwelt-Baildon, Michael |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Dettori, D. ELSEVIER |t miR-214 in stroma cells and tumor progression |d 2016 |g Amsterdam [u.a.] |w (DE-627)ELV019637179 |
| 773 | 1 | 8 | |g volume:94 |g year:2015 |g number:2 |g pages:179-188 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.critrevonc.2014.12.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2016 | ||
| 912 | |a GBV_ILN_2048 | ||
| 936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 94 |j 2015 |e 2 |h 179-188 |g 10 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
u h uh |
|---|---|
| matchkey_str |
holtickudoalbrechtmelaniechemnitzjensmth:2015----:oprsnfoearwesseihrlloalgnihmtpitctmelrnpattofreaooiamlgace |
| hierarchy_sort_str |
2015transfer abstract |
| bklnumber |
44.52 |
| publishDate |
2015 |
| allfields |
10.1016/j.critrevonc.2014.12.007 doi GBVA2015017000005.pica (DE-627)ELV039853918 (ELSEVIER)S1040-8428(14)00215-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Holtick, Udo verfasserin aut Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis 2015transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. Graft versus host disease Elsevier Stem cell source Elsevier Peripheral blood Elsevier Bone marrow Elsevier Allogeneic stem cell transplantation Elsevier Albrecht, Melanie oth Chemnitz, Jens M. oth Theurich, Sebastian oth Shimabukuro-Vornhagen, Alexander oth Skoetz, Nicole oth Scheid, Christof oth von Bergwelt-Baildon, Michael oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:94 year:2015 number:2 pages:179-188 extent:10 https://doi.org/10.1016/j.critrevonc.2014.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 94 2015 2 179-188 10 045F 610 |
| spelling |
10.1016/j.critrevonc.2014.12.007 doi GBVA2015017000005.pica (DE-627)ELV039853918 (ELSEVIER)S1040-8428(14)00215-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Holtick, Udo verfasserin aut Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis 2015transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. Graft versus host disease Elsevier Stem cell source Elsevier Peripheral blood Elsevier Bone marrow Elsevier Allogeneic stem cell transplantation Elsevier Albrecht, Melanie oth Chemnitz, Jens M. oth Theurich, Sebastian oth Shimabukuro-Vornhagen, Alexander oth Skoetz, Nicole oth Scheid, Christof oth von Bergwelt-Baildon, Michael oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:94 year:2015 number:2 pages:179-188 extent:10 https://doi.org/10.1016/j.critrevonc.2014.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 94 2015 2 179-188 10 045F 610 |
| allfields_unstemmed |
10.1016/j.critrevonc.2014.12.007 doi GBVA2015017000005.pica (DE-627)ELV039853918 (ELSEVIER)S1040-8428(14)00215-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Holtick, Udo verfasserin aut Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis 2015transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. Graft versus host disease Elsevier Stem cell source Elsevier Peripheral blood Elsevier Bone marrow Elsevier Allogeneic stem cell transplantation Elsevier Albrecht, Melanie oth Chemnitz, Jens M. oth Theurich, Sebastian oth Shimabukuro-Vornhagen, Alexander oth Skoetz, Nicole oth Scheid, Christof oth von Bergwelt-Baildon, Michael oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:94 year:2015 number:2 pages:179-188 extent:10 https://doi.org/10.1016/j.critrevonc.2014.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 94 2015 2 179-188 10 045F 610 |
| allfieldsGer |
10.1016/j.critrevonc.2014.12.007 doi GBVA2015017000005.pica (DE-627)ELV039853918 (ELSEVIER)S1040-8428(14)00215-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Holtick, Udo verfasserin aut Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis 2015transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. Graft versus host disease Elsevier Stem cell source Elsevier Peripheral blood Elsevier Bone marrow Elsevier Allogeneic stem cell transplantation Elsevier Albrecht, Melanie oth Chemnitz, Jens M. oth Theurich, Sebastian oth Shimabukuro-Vornhagen, Alexander oth Skoetz, Nicole oth Scheid, Christof oth von Bergwelt-Baildon, Michael oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:94 year:2015 number:2 pages:179-188 extent:10 https://doi.org/10.1016/j.critrevonc.2014.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 94 2015 2 179-188 10 045F 610 |
| allfieldsSound |
10.1016/j.critrevonc.2014.12.007 doi GBVA2015017000005.pica (DE-627)ELV039853918 (ELSEVIER)S1040-8428(14)00215-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Holtick, Udo verfasserin aut Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis 2015transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. • Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. Graft versus host disease Elsevier Stem cell source Elsevier Peripheral blood Elsevier Bone marrow Elsevier Allogeneic stem cell transplantation Elsevier Albrecht, Melanie oth Chemnitz, Jens M. oth Theurich, Sebastian oth Shimabukuro-Vornhagen, Alexander oth Skoetz, Nicole oth Scheid, Christof oth von Bergwelt-Baildon, Michael oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:94 year:2015 number:2 pages:179-188 extent:10 https://doi.org/10.1016/j.critrevonc.2014.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 94 2015 2 179-188 10 045F 610 |
| language |
English |
| source |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:94 year:2015 number:2 pages:179-188 extent:10 |
| sourceStr |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:94 year:2015 number:2 pages:179-188 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Therapie |
| institution |
findex.gbv.de |
| topic_facet |
Graft versus host disease Stem cell source Peripheral blood Bone marrow Allogeneic stem cell transplantation |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
miR-214 in stroma cells and tumor progression |
| authorswithroles_txt_mv |
Holtick, Udo @@aut@@ Albrecht, Melanie @@oth@@ Chemnitz, Jens M. @@oth@@ Theurich, Sebastian @@oth@@ Shimabukuro-Vornhagen, Alexander @@oth@@ Skoetz, Nicole @@oth@@ Scheid, Christof @@oth@@ von Bergwelt-Baildon, Michael @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV019637179 |
| dewey-sort |
3610 |
| id |
ELV039853918 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV039853918</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625230105.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2014.12.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015017000005.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV039853918</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(14)00215-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Holtick, Udo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Graft versus host disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Stem cell source</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Peripheral blood</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bone marrow</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Allogeneic stem cell transplantation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albrecht, Melanie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chemnitz, Jens M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Theurich, Sebastian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shimabukuro-Vornhagen, Alexander</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Skoetz, Nicole</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scheid, Christof</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">von Bergwelt-Baildon, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:94</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:179-188</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2014.12.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">94</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">179-188</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Holtick, Udo |
| spellingShingle |
Holtick, Udo ddc 610 bkl 44.52 Elsevier Graft versus host disease Elsevier Stem cell source Elsevier Peripheral blood Elsevier Bone marrow Elsevier Allogeneic stem cell transplantation Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis |
| authorStr |
Holtick, Udo |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV019637179 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.52 bkl Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis Graft versus host disease Elsevier Stem cell source Elsevier Peripheral blood Elsevier Bone marrow Elsevier Allogeneic stem cell transplantation Elsevier |
| topic |
ddc 610 bkl 44.52 Elsevier Graft versus host disease Elsevier Stem cell source Elsevier Peripheral blood Elsevier Bone marrow Elsevier Allogeneic stem cell transplantation |
| topic_unstemmed |
ddc 610 bkl 44.52 Elsevier Graft versus host disease Elsevier Stem cell source Elsevier Peripheral blood Elsevier Bone marrow Elsevier Allogeneic stem cell transplantation |
| topic_browse |
ddc 610 bkl 44.52 Elsevier Graft versus host disease Elsevier Stem cell source Elsevier Peripheral blood Elsevier Bone marrow Elsevier Allogeneic stem cell transplantation |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m a ma j m c jm jmc s t st a s v asv n s ns c s cs b b m v bbm bbmv |
| hierarchy_parent_title |
miR-214 in stroma cells and tumor progression |
| hierarchy_parent_id |
ELV019637179 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
miR-214 in stroma cells and tumor progression |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV019637179 |
| title |
Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis |
| ctrlnum |
(DE-627)ELV039853918 (ELSEVIER)S1040-8428(14)00215-7 |
| title_full |
Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis |
| author_sort |
Holtick, Udo |
| journal |
miR-214 in stroma cells and tumor progression |
| journalStr |
miR-214 in stroma cells and tumor progression |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
179 |
| author_browse |
Holtick, Udo |
| container_volume |
94 |
| physical |
10 |
| class |
610 610 DE-600 610 VZ 44.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Holtick, Udo |
| doi_str_mv |
10.1016/j.critrevonc.2014.12.007 |
| dewey-full |
610 |
| title_sort |
comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis |
| title_auth |
Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis |
| abstract |
• Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. |
| abstractGer |
• Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. |
| abstract_unstemmed |
• Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 |
| container_issue |
2 |
| title_short |
Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis |
| url |
https://doi.org/10.1016/j.critrevonc.2014.12.007 |
| remote_bool |
true |
| author2 |
Albrecht, Melanie Chemnitz, Jens M. Theurich, Sebastian Shimabukuro-Vornhagen, Alexander Skoetz, Nicole Scheid, Christof von Bergwelt-Baildon, Michael |
| author2Str |
Albrecht, Melanie Chemnitz, Jens M. Theurich, Sebastian Shimabukuro-Vornhagen, Alexander Skoetz, Nicole Scheid, Christof von Bergwelt-Baildon, Michael |
| ppnlink |
ELV019637179 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.critrevonc.2014.12.007 |
| up_date |
2024-07-06T21:39:48.614Z |
| _version_ |
1803867378015010816 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV039853918</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625230105.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2014.12.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015017000005.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV039853918</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(14)00215-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Holtick, Udo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Peripheral blood stem cells have replaced bone marrow as main stem cell source in the last two decades. • Transplant indications, conditioning regimens and donor selection criteria have clearly changed in the last 10–15 years. • It is under debate, whether transplant outcomes might be influenced by the choice of the stem cell source against the background of current transplant settings. • This systematic review demonstrates that the current clinical standard to use peripheral blood stem cells instead of bone marrow for allo-SCT is not inferior with regard to the primary outcome overall survival although graft-versus-host disease is increased. • Data must be collected analysing more recently treated patients with regard to reduced-intensity and mismatch transplants as well as transplants of elderly patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Graft versus host disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Stem cell source</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Peripheral blood</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bone marrow</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Allogeneic stem cell transplantation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albrecht, Melanie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chemnitz, Jens M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Theurich, Sebastian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shimabukuro-Vornhagen, Alexander</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Skoetz, Nicole</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scheid, Christof</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">von Bergwelt-Baildon, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:94</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:179-188</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2014.12.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">94</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">179-188</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4018583 |